NCT06026514View on ClinicalTrials.gov

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 18, 2023

Primary Completion Date

January 16, 2025

Study Completion Date

June 30, 2025

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

B/HPIV3/S-6P

Intranasal vaccine.

Trial Locations (1)

20215

Johns Hopkins Bloomberg School of Public Health, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

collaborator

National Institutes of Health (NIH)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH